<p>TFG 资产管理 GP 有限公司在第二季度根据其最近向证券交易委员会提交的 13F 文件，购买了 Dyne Therapeutics, Inc.（NASDAQ:DYN - 免费报告）的新股份。该基金购买了 138,375 股公司股票，价值约为 1,317,000 美元。Dyne Therapeutics 占 TFG 资产管理 GP 有限公司持有的股份的 0.2%，使其成为该公司第 28 大持仓。截至其最近向证券交易委员会提交的文件，TFG 资产管理 GP 有限公司持有 Dyne Therapeutics 约 0.10% 的股份。</p>
<p>其他机构投资者和对冲基金最近也调整了对该公司的持股。RA Capital Management L.P.在第一季度将其在 Dyne Therapeutics 的持仓增加了 52.2%。RA Capital Management L.P.目前拥有 9,714,392 股公司股票，价值为 101,613,000 美元，此前在上个季度又购买了 3,333,248 股。Braidwell LP 在第一季度将其在 Dyne Therapeutics 的持仓提高了 431.6%。Braidwell LP 目前拥有 3,621,344 股公司股票，价值为 37,879,000 美元，此前在上个季度又购买了 2,940,162 股。Armistice Capital LLC 在第一季度将其在 Dyne Therapeutics 的持仓提高了 187.0%。Armistice Capital LLC 目前拥有 2,768,000 股公司股票，价值为 28,953,000 美元，此前在上个季度又购买了 1,803,482 股。Vestal Point Capital LP 在第一季度购买了 Dyne Therapeutics 的新持仓，价值约为 18,828,000 美元。最后，Saturn V Capital Management LP 在第二季度购买了 Dyne Therapeutics 的新持仓，价值为 13,856,000 美元。对冲基金和其他机构投资者持有该公司 96.68% 的股份。</p>
<p>获取 <strong>Dyne Therapeutics</strong> 警报：</p>
<h2>Dyne Therapeutics 股票下跌 1.4%</h2>
<p>周五，DYN 的开盘价为 19.42 美元。Dyne Therapeutics, Inc.的 12 个月低点为 6.36 美元，12 个月高点为 27.59 美元。该公司的流动比率为 13.47，速动比率为 13.47，债务与股本比率为 0.14。该公司的 50 日移动平均价格为 19.05 美元，200 日移动平均价格为 14.22 美元。该公司的市值为 27.7 亿美元，市盈率为-5.31，贝塔值为 1.30。</p>
<p>Dyne Therapeutics（NASDAQ:DYN - 获取免费报告）最后一次公布季度财报是在 11 月 5 日，星期三。该公司报告季度每股收益为（0.76 美元），超出市场共识预期的（0.81 美元）0.05 美元。平均而言，股票分析师预计 Dyne Therapeutics, Inc.在当前年度将发布-3.44 的每股收益。</p>
<h2>华尔街分析师观点</h2>
<p>一些分析师最近对该股票发布了报告。Robert W. Baird 在周一对 Dyne Therapeutics 的股票设定了 30.00 美元的目标价。Lifesci Capital 在 10 月 14 日的研究报告中将 Dyne Therapeutics 的评级上调至 “强力买入”。加拿大皇家银行在 11 月 6 日的报告中将 Dyne Therapeutics 的目标价从 23.00 美元上调至 30.00 美元，并给予该股票 “跑赢大盘” 的评级。Oppenheimer 在周三将 Dyne Therapeutics 的评级从 “市场表现” 上调至 “跑赢大盘”，并将该公司的目标价从 11.00 美元提高至 40.00 美元。最后，HC Wainwright 在周一将 Dyne Therapeutics 的目标价从 46.00 美元上调至 60.00 美元，并给予该股票 “买入” 评级。三位投资分析师对该股票给予了强力买入评级，十三位给予了买入评级，两位给予了持有评级，一位给予了卖出评级。根据 MarketBeat 的数据，Dyne Therapeutics 目前的共识评级为 “适度买入”，平均目标价为 38.59 美元。</p>
<p><strong>获取我们对 DYN 的最新分析</strong></p>
<h2>关于 Dyne Therapeutics</h2>
<p>（免费报告）</p>
<p>Dyne Therapeutics, Inc.是一家临床阶段的肌肉疾病公司，作为一家生物技术公司，专注于推进针对美国基因驱动的肌肉疾病的治疗。它正在开发一系列肌肉疾病治疗方案，包括肌强直性营养不良症 1 型、杜氏肌营养不良症和面肩肱肌营养不良症，以及使用其 FORCE 平台针对罕见骨骼肌、心脏和代谢肌肉疾病的疾病修正治疗。</p>
<h2>推荐故事</h2>
<ul>
<li>五只我们更看好的股票超过 Dyne Therapeutics</li>
<li>安静期到期的解释</li>
<li>分红强势股：3 只为长期投资而生的蓝筹股</li>
<li>标普 500 股票告诉投资者市场的什么？</li>
<li>2026 年要避免的 3 只最近被下调的股票</li>
<li>现在购买的 3 只沃伦·巴菲特股票</li>
<li>芯片热潮回归：3 只有巨大收益潜力的股票</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9RFlO?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9RFlO"/></p>
<p><em>此即时新闻警报由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或评论发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在 Dyne Therapeutics 吗？</h2>
<p>在考虑 Dyne Therapeutics 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师正在悄悄向客户推荐的股票，以便在更广泛的市场注意到之前购买……而 Dyne Therapeutics 并不在名单上。</p>
<p>虽然 Dyne Therapeutics 目前在分析师中获得了适度买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>查看这五只股票</p>

<p>TFG 资产管理 GP 有限公司在第二季度收购了 138,375 股 Dyne Therapeutics, Inc.（纳斯达克代码：DYN），价值 1,317,000 美元。Dyne Therapeutics 占 TFG 持股的 0.2%。其他机构投资者如 RA Capital、Braidwell LP 和 Armistice Capital 也增加了他们的持股。Dyne Therapeutics 的股票评级为 “适度买入”，平均目标价格为 38.59 美元。该公司专注于基因驱动的肌肉疾病治疗</p>

<p>TFG Asset Management GP Ltd bought a new position in shares of Dyne Therapeutics, Inc. (NASDAQ:DYN - Free Report) in the 2nd quarter, according to its most recent 13F filing with the Securities &amp; Exchange Commission. The fund bought 138,375 shares of the company's stock, valued at approximately $1,317,000. Dyne Therapeutics makes up 0.2% of TFG Asset Management GP Ltd's holdings, making the stock its 28th biggest position. TFG Asset Management GP Ltd owned about 0.10% of Dyne Therapeutics as of its most recent filing with the Securities &amp; Exchange Commission.</p>
<div class="lb-trans"><p>TFG 资产管理 GP 有限公司在第二季度根据其最近向证券交易委员会提交的 13F 文件，购买了 Dyne Therapeutics, Inc.（NASDAQ:DYN - 免费报告）的新股份。该基金购买了 138,375 股公司股票，价值约为 1,317,000 美元。Dyne Therapeutics 占 TFG 资产管理 GP 有限公司持有的股份的 0.2%，使其成为该公司第 28 大持仓。截至其最近向证券交易委员会提交的文件，TFG 资产管理 GP 有限公司持有 Dyne Therapeutics 约 0.10% 的股份。</p>
</div><p>Other institutional investors and hedge funds have also recently modified their holdings of the company. RA Capital Management L.P. boosted its position in shares of Dyne Therapeutics by 52.2% during the 1st quarter. RA Capital Management L.P. now owns 9,714,392 shares of the company's stock valued at $101,613,000 after acquiring an additional 3,333,248 shares during the last quarter. Braidwell LP lifted its position in Dyne Therapeutics by 431.6% during the first quarter. Braidwell LP now owns 3,621,344 shares of the company's stock valued at $37,879,000 after purchasing an additional 2,940,162 shares during the last quarter. Armistice Capital LLC lifted its position in Dyne Therapeutics by 187.0% during the first quarter. Armistice Capital LLC now owns 2,768,000 shares of the company's stock valued at $28,953,000 after purchasing an additional 1,803,482 shares during the last quarter. Vestal Point Capital LP purchased a new position in Dyne Therapeutics in the 1st quarter worth approximately $18,828,000. Finally, Saturn V Capital Management LP bought a new position in shares of Dyne Therapeutics in the 2nd quarter worth $13,856,000. Hedge funds and other institutional investors own 96.68% of the company's stock.</p>
<div class="lb-trans"><p>其他机构投资者和对冲基金最近也调整了对该公司的持股。RA Capital Management L.P.在第一季度将其在 Dyne Therapeutics 的持仓增加了 52.2%。RA Capital Management L.P.目前拥有 9,714,392 股公司股票，价值为 101,613,000 美元，此前在上个季度又购买了 3,333,248 股。Braidwell LP 在第一季度将其在 Dyne Therapeutics 的持仓提高了 431.6%。Braidwell LP 目前拥有 3,621,344 股公司股票，价值为 37,879,000 美元，此前在上个季度又购买了 2,940,162 股。Armistice Capital LLC 在第一季度将其在 Dyne Therapeutics 的持仓提高了 187.0%。Armistice Capital LLC 目前拥有 2,768,000 股公司股票，价值为 28,953,000 美元，此前在上个季度又购买了 1,803,482 股。Vestal Point Capital LP 在第一季度购买了 Dyne Therapeutics 的新持仓，价值约为 18,828,000 美元。最后，Saturn V Capital Management LP 在第二季度购买了 Dyne Therapeutics 的新持仓，价值为 13,856,000 美元。对冲基金和其他机构投资者持有该公司 96.68% 的股份。</p>
</div><p>Get <strong>Dyne Therapeutics</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Dyne Therapeutics</strong> 警报：</p>
</div><h2>Dyne Therapeutics Stock Down 1.4%</h2>
<div class="lb-trans"><h2>Dyne Therapeutics 股票下跌 1.4%</h2>
</div><p>DYN opened at $19.42 on Friday. Dyne Therapeutics, Inc. has a 12 month low of $6.36 and a 12 month high of $27.59. The company has a current ratio of 13.47, a quick ratio of 13.47 and a debt-to-equity ratio of 0.14. The business's 50-day moving average price is $19.05 and its 200-day moving average price is $14.22. The company has a market cap of $2.77 billion, a P/E ratio of -5.31 and a beta of 1.30.</p>
<div class="lb-trans"><p>周五，DYN 的开盘价为 19.42 美元。Dyne Therapeutics, Inc.的 12 个月低点为 6.36 美元，12 个月高点为 27.59 美元。该公司的流动比率为 13.47，速动比率为 13.47，债务与股本比率为 0.14。该公司的 50 日移动平均价格为 19.05 美元，200 日移动平均价格为 14.22 美元。该公司的市值为 27.7 亿美元，市盈率为-5.31，贝塔值为 1.30。</p>
</div><p>Dyne Therapeutics (NASDAQ:DYN - Get Free Report) last announced its quarterly earnings results on Wednesday, November 5th. The company reported ($0.76) earnings per share for the quarter, beating the consensus estimate of ($0.81) by $0.05. On average, equities analysts expect that Dyne Therapeutics, Inc. will post -3.44 EPS for the current year.</p>
<div class="lb-trans"><p>Dyne Therapeutics（NASDAQ:DYN - 获取免费报告）最后一次公布季度财报是在 11 月 5 日，星期三。该公司报告季度每股收益为（0.76 美元），超出市场共识预期的（0.81 美元）0.05 美元。平均而言，股票分析师预计 Dyne Therapeutics, Inc.在当前年度将发布-3.44 的每股收益。</p>
</div><h2>Wall Street Analyst Weigh In</h2>
<div class="lb-trans"><h2>华尔街分析师观点</h2>
</div><p>A number of analysts have recently issued reports on the stock. Robert W. Baird set a $30.00 price objective on shares of Dyne Therapeutics in a report on Monday. Lifesci Capital upgraded Dyne Therapeutics to a &#34;strong-buy&#34; rating in a research report on Tuesday, October 14th. Royal Bank Of Canada upped their price objective on Dyne Therapeutics from $23.00 to $30.00 and gave the stock an &#34;outperform&#34; rating in a report on Thursday, November 6th. Oppenheimer upgraded Dyne Therapeutics from a &#34;market perform&#34; rating to an &#34;outperform&#34; rating and increased their price objective for the company from $11.00 to $40.00 in a research report on Wednesday. Finally, HC Wainwright boosted their target price on Dyne Therapeutics from $46.00 to $60.00 and gave the stock a &#34;buy&#34; rating in a research report on Monday. Three investment analysts have rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, Dyne Therapeutics currently has a consensus rating of &#34;Moderate Buy&#34; and an average target price of $38.59.</p>
<div class="lb-trans"><p>一些分析师最近对该股票发布了报告。Robert W. Baird 在周一对 Dyne Therapeutics 的股票设定了 30.00 美元的目标价。Lifesci Capital 在 10 月 14 日的研究报告中将 Dyne Therapeutics 的评级上调至 “强力买入”。加拿大皇家银行在 11 月 6 日的报告中将 Dyne Therapeutics 的目标价从 23.00 美元上调至 30.00 美元，并给予该股票 “跑赢大盘” 的评级。Oppenheimer 在周三将 Dyne Therapeutics 的评级从 “市场表现” 上调至 “跑赢大盘”，并将该公司的目标价从 11.00 美元提高至 40.00 美元。最后，HC Wainwright 在周一将 Dyne Therapeutics 的目标价从 46.00 美元上调至 60.00 美元，并给予该股票 “买入” 评级。三位投资分析师对该股票给予了强力买入评级，十三位给予了买入评级，两位给予了持有评级，一位给予了卖出评级。根据 MarketBeat 的数据，Dyne Therapeutics 目前的共识评级为 “适度买入”，平均目标价为 38.59 美元。</p>
</div><p><strong>Get Our Latest Analysis on DYN</strong></p>
<div class="lb-trans"><p><strong>获取我们对 DYN 的最新分析</strong></p>
</div><h2>About Dyne Therapeutics</h2>
<div class="lb-trans"><h2>关于 Dyne Therapeutics</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免费报告）</p>
</div><p>Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.</p>
<div class="lb-trans"><p>Dyne Therapeutics, Inc.是一家临床阶段的肌肉疾病公司，作为一家生物技术公司，专注于推进针对美国基因驱动的肌肉疾病的治疗。它正在开发一系列肌肉疾病治疗方案，包括肌强直性营养不良症 1 型、杜氏肌营养不良症和面肩肱肌营养不良症，以及使用其 FORCE 平台针对罕见骨骼肌、心脏和代谢肌肉疾病的疾病修正治疗。</p>
</div><h2>Recommended Stories</h2>
<div class="lb-trans"><h2>推荐故事</h2>
</div><ul>
<li>Five stocks we like better than Dyne Therapeutics</li>
<li>Quiet Period Expirations Explained</li>
<li>Dividend Powerhouses: 3 Blue-Chip Stocks Built for the Long Haul</li>
<li>What Do S&amp;P 500 Stocks Tell Investors About the Market?</li>
<li>3 Recently Downgraded Stocks to Avoid in 2026</li>
<li>3 Warren Buffett Stocks to Buy Now</li>
<li>The Chip Boom Is Back: 3 Stocks Positioned for Huge Gains</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们更看好的股票超过 Dyne Therapeutics</li>
<li>安静期到期的解释</li>
<li>分红强势股：3 只为长期投资而生的蓝筹股</li>
<li>标普 500 股票告诉投资者市场的什么？</li>
<li>2026 年要避免的 3 只最近被下调的股票</li>
<li>现在购买的 3 只沃伦·巴菲特股票</li>
<li>芯片热潮回归：3 只有巨大收益潜力的股票</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9RFlO" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NASDAQ&amp;Symbol=DYN"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻警报由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或评论发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Dyne Therapeutics Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 Dyne Therapeutics 吗？</h2>
</div><p>Before you consider Dyne Therapeutics, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 Dyne Therapeutics 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Dyne Therapeutics wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师正在悄悄向客户推荐的股票，以便在更广泛的市场注意到之前购买……而 Dyne Therapeutics 并不在名单上。</p>
</div><p>While Dyne Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Dyne Therapeutics 目前在分析师中获得了适度买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看这五只股票</p>
</div>

TFG 资产管理 GP 有限公司收购了 Dyne Therapeutics, Inc.的新股份 $DYN